ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
REGENXBIO Inc

REGENXBIO Inc (RGNX)

7.30
-0.02
(-0.27%)
Closed February 16 3:00PM
7.30
0.00
(0.00%)
After Hours: 6:58PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
7.30
Bid
7.30
Ask
7.78
Volume
700,891
7.23 Day's Range 7.76
6.56 52 Week Range 28.80
Market Cap
Previous Close
7.32
Open
7.25
Last Trade Time
Financial Volume
US$ 5,168,433
VWAP
7.3741
Average Volume (3m)
1,286,294
Shares Outstanding
49,545,071
Dividend Yield
-
PE Ratio
-1.37
Earnings Per Share (EPS)
-5.32
Revenue
90.24M
Net Profit
-263.49M

About REGENXBIO Inc

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
REGENXBIO Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RGNX. The last closing price for REGENXBIO was US$7.32. Over the last year, REGENXBIO shares have traded in a share price range of US$ 6.56 to US$ 28.80.

REGENXBIO currently has 49,545,071 shares outstanding. The market capitalization of REGENXBIO is US$362.67 million. REGENXBIO has a price to earnings ratio (PE ratio) of -1.37.

RGNX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.25-14.61988304098.558.666.9157120527.53718415CS
40.030.412654745537.278.74516.9157382747.80461CS
12-1.85-20.2185792359.1510.526.5612862948.1212344CS
26-5.03-40.794809407912.3313.486.568988979.07654507CS
52-9.1-55.48780487816.428.86.5675534312.19338236CS
156-18.03-71.180418476125.3335.736.5653100817.11663774CS
260-46.96-86.546258754154.2654.636.5648104823.54042116CS

RGNX - Frequently Asked Questions (FAQ)

What is the current REGENXBIO share price?
The current share price of REGENXBIO is US$ 7.30
How many REGENXBIO shares are in issue?
REGENXBIO has 49,545,071 shares in issue
What is the market cap of REGENXBIO?
The market capitalisation of REGENXBIO is USD 362.67M
What is the 1 year trading range for REGENXBIO share price?
REGENXBIO has traded in the range of US$ 6.56 to US$ 28.80 during the past year
What is the PE ratio of REGENXBIO?
The price to earnings ratio of REGENXBIO is -1.37
What is the cash to sales ratio of REGENXBIO?
The cash to sales ratio of REGENXBIO is 4.01
What is the reporting currency for REGENXBIO?
REGENXBIO reports financial results in USD
What is the latest annual turnover for REGENXBIO?
The latest annual turnover of REGENXBIO is USD 90.24M
What is the latest annual profit for REGENXBIO?
The latest annual profit of REGENXBIO is USD -263.49M
What is the registered address of REGENXBIO?
The registered address for REGENXBIO is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the REGENXBIO website address?
The website address for REGENXBIO is www.regenxbio.com
Which industry sector does REGENXBIO operate in?
REGENXBIO operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
430.77k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.03M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
164.82k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.4M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
489.28M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
417.31M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
INTCIntel Corporation
US$ 23.60
(-2.20%)
230.26M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
194.99M

RGNX Discussion

View Posts
Monksdream Monksdream 2 months ago
RGNX, under $8
👍️0
Monksdream Monksdream 4 months ago
RGNX under $10
👍️0
crudeoil24 crudeoil24 3 years ago
36M share trading float.

RGNX
👍️0
crudeoil24 crudeoil24 3 years ago
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp
👍️0
StockLearner2011 StockLearner2011 6 years ago
I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!
👍️0
Zmill Zmill 6 years ago
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/
👍️0
BlackEyePatch BlackEyePatch 6 years ago
Strong buy @ 50!!!!
👍️0
stocktrademan stocktrademan 6 years ago
RGNX buy 66.90























normal chart




log chart



👍️0
StockLearner2011 StockLearner2011 7 years ago
Hope no more form 4s for insider selling
👍️0
StockLearner2011 StockLearner2011 7 years ago
Let’s see how tomorrow will be
👍️0
StockLearner2011 StockLearner2011 7 years ago
Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?
👍️0
StockLearner2011 StockLearner2011 7 years ago
$45 soon! Yummy
👍️0
stocktrademan stocktrademan 8 years ago
RGNX bullish 14.39



normal chart


log chart

👍️0
protagonist12 protagonist12 9 years ago
Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.
👍️0
floWteiuQ floWteiuQ 9 years ago
Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.
👍️0
protagonist12 protagonist12 9 years ago
RGNX no bid support, too early still, listed VC...
👍️0